Avadel Pharmaceuticals plc
Price Action
Technical Summary
STAGE 2 UPTRENDAvadel Pharmaceuticals plc is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 88), indicating clear outperformance against the broad market. Earnings growth of 101% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $21.57 | +0.30% | ABOVE |
| 50 SMA | $21.51 | +0.60% | ABOVE |
| 100 SMA | $19.87 | +8.89% | ABOVE |
| 150 SMA | $17.73 | +22.04% | ABOVE |
| 200 SMA | $15.62 | +38.56% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is AVDL in an uptrend right now?
AVDL has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, AVDL is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is AVDL overbought or oversold?
AVDL's RSI (14) is 62. The stock is in neutral territory, neither overbought nor oversold.
Is AVDL outperforming the market?
AVDL has a Relative Strength (RS) Rating of 88 out of 99. Yes, AVDL is a market leader, outperforming 88% of all stocks over the past 12 months.
Where is AVDL in its 52-week range?
AVDL is trading at $21.64, which is 92% of its 52-week high ($23.57) and 87% above its 52-week low ($8.44).
How volatile is AVDL?
AVDL has a Beta of 0.23 and 52-week volatility of 47%. It's less volatile than the S&P 500 - generally more stable.